More than 25 years ago we discovered the phosphoinositide 3-kinases or PI3K. To date more than 30 PI3K inhibitors have entered clinical trials and an inhibitor (idelalisib) that targets PI3K? was recently approved for treating B cell lymphomas. Our research and research from other labs over the past 25 years has revealed that the PI3K pathway evolved to control cell growth, primarily through regulation of cellular metabolism. The focus of this application is to understand the biochemical mechanisms by which phosphoinositide kinases control cellular metabolism. We expect to uncover new targets for pharmaceutical intervention in cancers, new biomarkers for predicting patients who are likely to respond to pathway inhibitors, and new insight into mechanisms of resistance to pathway inhibitors. The proposed research falls into three categories: 1) Evaluate the mechanism by which PI3K controls glucose metabolism and nucleotide synthesis and develop biomarkers to identify patients who are likely to respond to PI3K inhibitors and predict drug combinations that are likely to be more effective than single agents. We have recently found that the major effect of activating PI3K on glucose metabolism is activation of Rac1 and consequent activation of aldolase A due to release of aldolase A from the actin cytoskeleton. Importantly we find that aldolase A activation is required for deoxy-nucleotide triphosphate synthesis at rates needed for S phase progression in tumors with p53 and BRCA1 or PTEN mutations, explaining why these tumors can be dramatically shrunk by PI3K plus PARP inhibitors but not by AKT plus PARP inhibitors. 2) Evaluation of phosphatidylinositol-5- phosphate 4-kinases (PIP4K2A and PIP4K2B) as therapeutic targets in cancers lacking p53 function and determination of the biochemical mechanism by which these kinases become essential for tumor growth when p53 is defective. PIP4K2A and B generate PI-4,5-P2 from the low abundant and poorly characterized lipid PI-5-P. Recently we made the surprising observation that PIP4K2B?/? TP53-/- mice die as early embryos. Importantly, PIP4K2A-/-, PIP4K2B+/-, TP53-/- mice are viable and rarely develop cancers, suggesting that PIP4K2A/B inhibitors might be effective for treating cancers with genetic aberrations in p53. Our studies show that knocking down PIP4K2A and B causes metabolic stress in p53 mutant cancer cells. We propose to determine the mechanism by which loss of PIP4K2A and B only causes metabolic stress in the context of loss of p53. 3) Identification and characterization of PIP4K2A and B inhibitors and evaluation of inhibitors in pre-clinical models in order to provide pre-clinical proof of concept studies that will allow these inhibitors to progress into human cancer trials. We have identified inhibitors of PIP4K2A and B and shown that they mimic the effects of knockout or knockdown of these enzymes in regard to affecting growth of p53 mutant cell lines. We will evaluate whether these inhibitors are on target and determine whether they have an efficacy/toxicity ratio in vivo that would make them useful for treating cancers with p53 mutations.

Public Health Relevance

We have recently discovered that breast, ovarian and prostate tumors that have mutations or deletions in TP53 along with mutations or deletions in PTEN and/or BRCA1 are particularly sensitive to a combination therapy involving a phosphoinositide 3-kinase inhibitor and PARP inhibitor, due to the ability of PI3K inhibitors to impair deoxynucleotide synthesis and thereby induce DNA damage that cannot be repaired when PARP is inhibited. We will explore the biochemical mechanism by which these drugs cause synergy specifically in this mutational setting using a variety of pre-clinical models and with biopsies available from an ongoing clinical trial. We have also discovered that a distinct family of phosphoinositides kinases encoded by the genes PIP4K2A and PIP4K2B create a synthetic lethality when deleted in the context of TP53 mutant tissues in mice or in human cancer cell lines and are developing inhibitors of these enzymes for cancer therapy. 1

National Institute of Health (NIH)
National Cancer Institute (NCI)
Unknown (R35)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M2))
Program Officer
Yassin, Rihab R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2017) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov :
Ravez, Séverine; Corbet, Cyril; Spillier, Quentin et al. (2017) ?-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH). J Med Chem 60:1591-1597
Zheng, Yuxiang; Cantley, Lewis C (2017) Membrane Lipids Speak to Histones. Mol Cell 66:163-164
Mathur, Deepti; Stratikopoulos, Elias; Ozturk, Sait et al. (2017) PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov 7:380-390
Gupta, Amit; Anjomani-Virmouni, Sara; Koundouros, Nikos et al. (2017) PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell 65:999-1013.e7
Lee, Gina; Zheng, Yuxiang; Cho, Sungyun et al. (2017) Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling. Cell 171:1545-1558.e18
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2017) PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3K? inhibitors. Clin Cancer Res :
Thorpe, Lauren M; Spangle, Jennifer M; Ohlson, Carolynn E et al. (2017) PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?. Proc Natl Acad Sci U S A 114:7095-7100
Matulonis, U A; Wulf, G M; Barry, W T et al. (2017) Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 28:512-518
de Oliveira Taveira, Mateus; Nabavi, Sheida; Wang, Yuker et al. (2017) Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. J Cancer Res Clin Oncol 143:1255-1262

Showing the most recent 10 out of 14 publications